Compass Therapeutics
CMPX
37 hedge funds and large institutions have $202M invested in Compass Therapeutics in 2021 Q4 according to their latest regulatory filings, with 37 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
64.85% more ownership
Funds ownership: 0% → 64.85% (+65%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$71.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$22.8M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$17.7M |
| 4 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
+$14.6M |
| 5 |
CCM
Consonance Capital Management
New York
|
+$11.6M |
Top Sellers
CMPX Hedge Fund Activity: Q4 2021 in Review
37 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q4 2021, worth a combined $202M.
Buyers outnumbered sellers: 37 funds opened new CMPX positions and 0 closed out — a net gain of 37 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $71.8M.
- 37 institutional investors held Compass Therapeutics (CMPX) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $202M of Compass Therapeutics stock for Q4 2021.
- 37 funds opened new Compass Therapeutics positions in Q4 2021 and 0 closed out, a net change of +37 holders.
- The largest Compass Therapeutics buyer in Q4 2021 was OrbiMed, an estimated $71.8M added.
Based on aggregated 13F filings for Q4 2021.